(Q35026064)

5 August 2017

1 reference

title

Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs (English)

1 reference

5 August 2017

1 reference

ChEBI release 2020-05-28

Christian Bailly

1

1 reference

5 August 2017

1 January 2003

1 reference

Critical Reviews in Oncology Hematology

5 August 2017

1 reference

5 August 2017

45

1 reference

5 August 2017

91-108

1 reference

5 August 2017

1

1 reference

Diversity of DNA topoisomerases I and inhibitors.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Topoisomerase I inhibitors: selectivity and cellular resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

DNA topoisomerases: structure, function, and mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

1 reference

7 January 2021

Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

DNA sequence selectivity of topoisomerases and topoisomerase poisons.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Mapping in vivo topoisomerase I sites on simian virus 40 DNA: asymmetric distribution of sites on replicating molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A model for the mechanism of human topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The role of histidine 632 in catalysis by human topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Replacement of the active site tyrosine of vaccinia DNA topoisomerase by glutamate, cysteine or histidine converts the enzyme into a site-specific endonuclease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Catalytic mechanism of DNA topoisomerase IB.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Structure and hydration of the DNA-human topoisomerase I covalent complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Tissue-specific expression of the beta-subunit of tryptophan synthase in Camptotheca acuminata, an indole alkaloid-producing plant

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Alkaloid Biosynthesis[mdash]The Basis for Metabolic Engineering of Medicinal Plants

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Sites of accumulation of the antitumor alkaloid camptothecin in Camptotheca acuminata

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Rapid micro-assay of camptothecin in Camptotheca acuminata

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Irinotecan (CPT-11): pharmacology and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Modulation of camptothecin analogs in the treatment of cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

DX-8951f: summary of phase I clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Two new flavonol glycosides as DNA topoisomerase I poisons

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. I. Producing strain, fermentation, isolation, physico-chemical properties and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A series of enediynes as novel inhibitors of topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Synthesis, biological activity and comparative analysis of DNA binding affinities and human DNA topoisomerase I inhibitory activities of novel 12-alkoxy-benzo[c]phenanthridinium salts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Synthesis, topoisomerase I inhibition and antitumor cytotoxicity of 2,2':6',2"-, 2,2':6',3"- and 2,2':6',4"-terpyridine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Comparative QSAR studies on bibenzimidazoles and terbenzimidazoles inhibiting topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Topoisomerase I poisons and suppressors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A strategy for identifying novel, mechanistically unique inhibitors of topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Directing topoisomerase I mediated DNA cleavage to specific sites by camptothecin tethered to minor- and major-groove ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Sequence-specific trapping of topoisomerase I by DNA binding polyamide-camptothecin conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Preferential binding of the carboxylate form of camptothecin by human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Differential interactions of camptothecin lactone and carboxylate forms with human blood components.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Reduced albumin binding promotes the stability and activity of topotecan in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Chemical modification of antitumor alkaloids, 20(S)-camptothecin and 7-ethylcamptothecin: reaction of the E-lactone ring portion with hydrazine hydrate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Mappicine, a minor alkaloid from Mappia foetida miers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Synthesis and antileukemic activity of (+-)-20-deoxyaminocamptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Antitumor Agents. V. Synthesis and Antileukemic Activity of E-Ring-Modified (RS)-Camptothecin Analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Chemical modification of an antitumor alkaloid, 20(S)-camptothecin: E-lactone ring-modified water-soluble derivatives of 7-ethylcamptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Homocamptothecins: E-ring modified CPT analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Synthesis and evaluation of a novel E-ring modified alpha-hydroxy keto ether analogue of camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Synthesis of an analog of camptothecin by a general method

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Kinetics of in vitro hydrolysis of homocamptothecins as measured by fluorescence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Effects of camptothecin analogues on DNA transformations mediated by calf thymus and human DNA topoisomerases I.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Topoisomerase I-mediated DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Symposium: downstream from topoisomerase-DNA lesions: life-or-death consequences for the cell

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Signal transduction pathways leading to cell cycle arrest and apoptosis induced by DNA topoisomerase poisons

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Tumor cell death induced by topoisomerase-targeting drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Processing of topoisomerase I cleavable complexes into DNA damage by transcription.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Transcriptional consequences of topoisomerase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Determinants of CPT-11 and SN-38 activities in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Downregulation of topoisomerase I in differentiating human intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Antitumor activity of XR5944, a novel and potent topoisomerase poison

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900090-2

7 January 2021

10.1016/S1040-8428(02)00090-2

Identifiers

DOI

1 reference

release_qukf4de74rcitppkjbndkiispm

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qukf4de74rcitppkjbndkiispm

24 November 2022

mapped directly with Wikidata item

PubMed ID

12482574

1 reference

PubMed ID

12482574